For example, 47.1% (16/34) of pancreatic cancer, 46.9% (30/64) of NSCLC, and 36.4% (32/88) of colon cancer were HER2 mRNA-positive only. This evidence concerns the gene ERBB2 and pancreatic neoplasm.